Follow The Filings

SMMT Summit Therapeutics

Summit Therapeutics earnings company data as of 1:58 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 26 Oct EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by SMMT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SMMT insider trades
  • $104M bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Mahkam Zanganeh CEO
    Buy
    $50M 3,810,000 shares at $13.12 +0.7% to stake
    Traded Jun 12 Filed Jun 12
  2. Manmeet Singh Soni CFO
    Buy
    $722K 50,000 shares at $14.45 +1.6% to stake
    Traded Jun 4 Filed Jun 4
  3. Mahkam Zanganeh CEO
    Buy
    $1.5M 100,000 shares at $14.60 +0.4% to stake
    Traded Jun 4 Filed Jun 4
  4. Yu Xia Director
    Buy
    $10M 533,617 shares at $18.74 +1.7% to stake
    Traded Oct 21, 2025 Filed Oct 23, 2025
  5. Mahkam Zanganeh CEO
    Buy
    $500K 26,680 shares at $18.74 +53% to stake
    Traded Oct 21, 2025 Filed Oct 23, 2025

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A
8-K 1.01,3.02,5.03,8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 2.02,7.01,9.01
10-Q
424B5
8-K 1.01,9.01
8-K 8.01,9.01
8-K 5.07
8-K 7.01
424B5
8-K 8.01
8-K 8.01,9.01
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
8-K 2.02,7.01,9.01
10-K
8-K 8.01,9.01
8-K 2.02,7.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.